|
1
|
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
|
JAMA
|
2004
|
23.69
|
|
2
|
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
12.44
|
|
3
|
Estrogen plus progestin and the risk of coronary heart disease.
|
N Engl J Med
|
2003
|
10.06
|
|
4
|
Estrogen therapy and coronary-artery calcification.
|
N Engl J Med
|
2007
|
8.70
|
|
5
|
The Women's Health Initiative recruitment methods and results.
|
Ann Epidemiol
|
2003
|
8.42
|
|
6
|
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
|
JAMA
|
2013
|
7.19
|
|
7
|
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
6.51
|
|
8
|
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial.
|
JAMA
|
2003
|
5.26
|
|
9
|
Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial.
|
Ann Intern Med
|
2010
|
4.27
|
|
10
|
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
|
Am J Epidemiol
|
2009
|
3.33
|
|
11
|
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study.
|
Am J Epidemiol
|
2008
|
3.05
|
|
12
|
Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.
|
JAMA
|
2002
|
3.01
|
|
13
|
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
2.97
|
|
14
|
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women.
|
Am J Epidemiol
|
2008
|
2.79
|
|
15
|
Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists.
|
Menopause
|
2007
|
2.47
|
|
16
|
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative.
|
Circulation
|
2006
|
2.40
|
|
17
|
Multimarker prediction of coronary heart disease risk: the Women's Health Initiative.
|
J Am Coll Cardiol
|
2010
|
2.34
|
|
18
|
Comparison of the Framingham and Reynolds Risk scores for global cardiovascular risk prediction in the multiethnic Women's Health Initiative.
|
Circulation
|
2012
|
2.17
|
|
19
|
Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.
|
Arterioscler Thromb Vasc Biol
|
2008
|
2.04
|
|
20
|
Noakes misses the point.
|
S Afr Med J
|
2013
|
2.04
|
|
21
|
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.
|
Ann Intern Med
|
2014
|
1.87
|
|
22
|
Vasomotor symptoms and cardiovascular events in postmenopausal women.
|
Menopause
|
2011
|
1.72
|
|
23
|
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk.
|
Genome Med
|
2011
|
1.55
|
|
24
|
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study.
|
Menopause
|
2014
|
1.50
|
|
25
|
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.46
|
|
26
|
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trials.
|
J Hypertens
|
2014
|
1.45
|
|
27
|
Bone mineral density of American Indian and Alaska Native women compared with non-Hispanic white women: results from the Women's Health Initiative Study.
|
Menopause
|
2005
|
1.40
|
|
28
|
Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
|
Clin Trials
|
2007
|
1.33
|
|
29
|
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
|
Maturitas
|
2006
|
1.31
|
|
30
|
Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.07
|
|
31
|
Postmenopausal estrogen and progestin effects on the serum proteome.
|
Genome Med
|
2009
|
1.07
|
|
32
|
Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events.
|
Am J Cardiol
|
2008
|
1.03
|
|
33
|
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: executive summary.
|
Circulation
|
2004
|
0.98
|
|
34
|
Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study.
|
Menopause
|
2008
|
0.95
|
|
35
|
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.
|
Breast Cancer Res
|
2014
|
0.95
|
|
36
|
Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling.
|
Genome Med
|
2010
|
0.92
|
|
37
|
Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study.
|
Thromb Haemost
|
2005
|
0.87
|
|
38
|
Prescribing postmenopausal hormone therapy to women in their 50s in the post-Women's Health Initiative era.
|
Maturitas
|
2009
|
0.85
|
|
39
|
Estrogens and cardiovascular disease risk revisited: the Women's Health Initiative.
|
Curr Opin Lipidol
|
2013
|
0.84
|
|
40
|
Women's health initiative view of estrogen avoidance and all-cause mortality.
|
Am J Public Health
|
2013
|
0.84
|
|
41
|
The hormone therapy dilemma: women respond.
|
J Am Med Womens Assoc
|
2003
|
0.81
|
|
42
|
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials.
|
Circulation
|
2004
|
0.78
|
|
43
|
Study had insufficient power to investigate safety.
|
BMJ
|
2012
|
0.76
|
|
44
|
Theoretical Effects of Substituting Butter with Margarine on Risk of Cardiovascular Disease.
|
Epidemiology
|
2017
|
0.75
|
|
45
|
The cross-sectional association between vasomotor symptoms and hemostatic parameter levels in postmenopausal women.
|
Menopause
|
2016
|
0.75
|
|
46
|
"Preventing breast cancer in postmenopausal women by achievable diet modification: a missed opportunity in public health policy" (Dayal HH and Kalia A, The Breast 2010; 19: 309-311).
|
Breast
|
2010
|
0.75
|
|
47
|
Genetic variants in the MRPS30 region and postmenopausal breast cancer risk.
|
Genome Med
|
2012
|
0.75
|
|
48
|
Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes".
|
Am J Epidemiol
|
2020
|
0.75
|
|
49
|
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials.
|
Am J Epidemiol
|
2020
|
0.75
|
|
50
|
BIOMARKER CALIBRATED SODIUM AND POTASSIUM INTAKE AND CARDIOVASCULAR DISEASE RISK AMONG POSTMENOPAUSAL WOMEN.
|
Am J Epidemiol
|
2017
|
0.75
|